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Abstract
Harmful alcohol use is a leading cause of premature death and is associated with age-
related disease. Biological ageing is highly variable between individuals and may
deviate from chronological ageing, suggesting that biomarkers of biological ageing
(derived from DNA methylation or brain structural measures) may be clinically
relevant. Here, we investigated the relationships between alcohol phenotypes and
both brain and DNA methylation age estimates. First, using data from UK Biobank
and Generation Scotland, we tested the association between alcohol consumption
(units/week) or hazardous use (Alcohol Use Disorders Identification Test [AUDIT]
scores) and accelerated brain and epigenetic ageing in 20,258 and 8051 individuals,
respectively. Second, we used Mendelian randomisation (MR) to test for a causal
effect of alcohol consumption levels and alcohol use disorder (AUD) on biological
ageing. Alcohol use showed a consistent positive association with higher predicted
brain age (AUDIT-C: β = 0.053, p = 3.16  1013; AUDIT-P: β = 0.052,
p = 1.6  1013; total AUDIT score: β = 0.062, p = 5.52  1016; units/week:
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β = 0.078, p = 2.20  1016), and two DNA methylation-based estimates of ageing,
GrimAge (units/week: β = 0.053, p = 1.48  107) and PhenoAge (units/week:
β = 0.077, p = 2.18x1010). MR analyses revealed limited evidence for a causal effect
of AUD on accelerated brain ageing (β = 0.118, p = 0.044). However, this result
should be interpreted cautiously as the significant effect was driven by a single
genetic variant. We found no evidence for a causal effect of alcohol consumption
levels on accelerated biological ageing. Future studies investigating the mechanisms
associating alcohol use with accelerated biological ageing are warranted.
K E YWORD S
alcohol use, brain ageing, epigenetic ageing, Generation Scotland, Mendelian randomisation, UK
Biobank
1 | INTRODUCTION
Harmful alcohol use is a leading cause for premature death globally.1
Excessive alcohol use affects multiple tissues2 and is associated with an
increased risk for all-cause mortality3 and age-related diseases including
diabetes, liver diseases and dementia.4 A recent large-scale epidemio-
logical investigation has challenged the view that moderate alcohol
consumption can be beneficial, showing that even small amounts of
alcohol negatively impact on health.1 Ageing itself is a complex process
of progressive deterioration due to the accrual of cellular damage over
time,5 and rates of these age-associated biological processes vary
between individuals. This could account for some of the variation in
susceptibility to age-related disease and suggests that measures of bio-
logical ageing may be more clinically relevant than chronological age.6,7
Several biomarkers have been proposed to measure individual variation
in biological ageing, including those based on DNA methylation
(DNAm) or brain magnetic resonance imaging (MRI). To date, studies
investigating associations between alcohol use and biological ageing
have been limited to small sample sizes, report inconsistent findings
and have not probed the potential causality of these associations.
Recent analytical approaches, such as that developed by Cole
et al.,6 use machine learning algorithms trained to predict chronologi-
cal age from brain structural MRI data. Testing these algorithms on
new structural data produces a metric of brain age that correlates
strongly with chronological age, although its deviation from chrono-
logical age reflects accelerated/decelerated brain ageing.8 Accelerated
brain ageing predicts mortality in older adults and correlates with
cognitive and physical decline.9 Several epigenetic clocks have also
been used to characterise biological ageing and are hypothesised to
capture molecular processes involved in declining tissue function.10
These biomarkers use weighted averages of methylation levels at
specific cytosine-phosphate-guanine (CpG) sites to produce estimates
of epigenetic age. Similarly to brain age, a greater positive deviation in
DNAm age from chronological age predicts all-cause mortality11 and
has been linked to a range of age- and lifestyle-related health
outcomes, including exercise and diet,12 and cognitive ability and
decline.13,14
Previous work has associated alcohol use with the acceleration
of biological ageing, as measured by both brain and DNAm
ageing.12,15–19 Ning et al.15 showed that more frequent consumption
of alcohol was associated with a higher brain age relative to peers,
with the lowest brain age found in individuals who reported drinking
only occasionally. Higher alcohol intake frequency was also associated
with an older-appearing brain using multiple MRI modalities to predict
brain age.16 Similarly, higher levels of alcohol consumption across
30 years of follow-up were associated with reductions in grey matter
density and white matter structural integrity, suggesting that heavy
alcohol consumption may lead to accelerated brain ageing.2
Alcohol use is associated with variation in DNAm20; thus, investi-
gations into the associations between alcohol use and epigenetic age-
ing could allow insight into the shared molecular mechanisms
underlying harmful alcohol use and ageing. Previous studies have
reported complex relationships between alcohol consumption levels
and epigenetic ageing, with studies showing positive,18 negative12 and
non-linear19 associations. Additionally, a recent study suggests both
positive and negative genetic associations between various alcohol-
related traits and epigenetic ageing using LD score regression.21
Cross-sectional, observational epidemiological studies are prone
to bias from residual confounding and reverse causation, limiting the
investigations of cause–effect relationships. Genome-wide association
studies (GWASs) have identified several loci implicated in both the
clinical diagnosis of alcohol use disorder (AUD) and varying alcohol
consumption levels.22,23 These genetic variants can be utilised as
instruments to determine the most likely direction of effect between
a modifiable exposure, alcohol use and the outcome, biological ageing,
using Mendelian randomisation (MR).24 It follows the logic that if a
modifiable exposure (e.g. alcohol use) is the cause of an outcome
(e.g. accelerated biological ageing), then individuals with genetic vari-
ants predisposing them towards increased alcohol use should be more
likely to experience accelerated biological ageing.
Here, we investigated the relationship between alcohol use and
biological ageing using the largest brain imaging (N = 20,258) and
DNAm (N = 8051) datasets to date. We hypothesised that higher
levels of alcohol consumption would associate with both higher
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DNAm age and brain age and that these associations would reflect a
causal effect of higher alcohol use on accelerated biological ageing.
2 | METHODS AND MATERIALS
The UK Biobank (UKB) and the Generation Scotland: Scottish Family
Health Study (GS:SFHS) cohort data were used in the current study.
For a graphical representation of the samples and data available in
both of the cohorts for the current analyses, see Figure S1.
2.1 | Study populations: UKB
UKB comprises N = 502,617 individuals recruited from across the
United Kingdom.25 UKB received ethical approval from the National
Health Service (NHS) National Research Ethics Service North West
(reference: 11/NW/0382). The present study was carried out under
UKB project ID 4844. At the time of writing, we used the latest
available UKB neuroimaging (see protocol in Miller et al.25) release
consisting of N = 21,386 individuals. After removing extreme outliers
(defined as MRI measurements >5*SD from the mean), cases of image
acquisition problems and excluding previous or never drinkers,
N = 20,258 individuals were included in the present study (see
Table S1 and Figure S2 for demographics and sample selection).
2.1.1 | Alcohol consumption
Lifestyle measures were collected at baseline and online follow-up.
Alcohol use in units/week at baseline was calculated by converting
the sum of reported average weekly intake of red wine, champagne
plus white wine, beer plus cider, spirits, fortified wine and other
alcoholic drinks into alcohol units. At online follow-up, a subset of
participants (N = 14,710) completed the Alcohol Use Disorders
Identification Test (AUDIT), a 10-item screening tool developed by the
World Health Organisation26 to assess alcohol consumption and
alcohol-related behaviours and problems. To examine the relationship
between alcohol use and brain age, we used four measures of alcohol
consumption: alcohol units/week and three measures from the AUDIT
questionnaire—a composite score of alcohol consumption (AUDIT-C;
sum of Questions 1–3), problematic alcohol use (AUDIT-P; sum of
Questions 4–10) and the total score across all items (AUDIT-T).
2.1.2 | Brain age estimates
We utilised a measure of brain age derived from structural
T1-weighted MRI data as described by Cole et al.6 and implemented
using the brainageR software package (https://github.com/james-
cole/brainageR). In the sample of current drinkers, the correlation
between brain age and chronological age was r = 0.734,
p < 2.2  1016 (full demographics in Table S1). This measure was
subsequently residualised over chronological age, sex, imaging site
(Manchester/Newcastle) and scanner head position X, Y and Z coordi-
nates. The residualised brain age measure reflected deviation of brain
age from chronological age (controlling for aforementioned
covariates), with positive values representing accelerated brain ageing.
2.2 | Study populations: Generation Scotland
GS:SFHS cohort comprises 24,000 individuals aged ≥18 years at
recruitment and is described in detail elsewhere.27 At baseline, partici-
pants were assessed for a range of health, demographic and lifestyle
factors and provided samples for DNA extraction. GS:SFHS has been
granted ethical approval from the NHS Tayside Committee on Medical
Research Ethics, on behalf of the NHS (reference: 05/S1401/89) and
has Research Tissue Bank status (reference: 15/ES/0040). The present
study includes individuals for whom information about alcohol con-
sumption, smoking, body mass index (BMI) and DNAm data (profiled
in two sets; see below) was acquired at baseline (full demographics in
Table S2).
2.2.1 | Alcohol consumption
We used self-reported units/week as a quantification of a person's
alcohol consumption. The present study includes individuals who
reported being current drinkers; extreme outliers (defined as partici-
pants with alcohol consumption in units/week >4* standard deviations
[SD] from the mean) were additionally excluded from the analysis. For
a comparison between the GS:SFHS participants included and not
included in the current study, see Table S14.
2.2.2 | DNAm profiling
Whole blood genomic DNA samples were treated with sodium
bisulphite using the EZ-96 DNA Methylation Kit (Zymo Research,
Irvine, California), following the manufacturer's instructions. Genome-
wide DNAm was profiled using the Infinium MethylationEPIC
BeadChip (Illumina Inc., San Diego, California) in accordance with the
manufacturer's protocol. DNAm was profiled in 9778 participants
across two processing sets (Set 1 N = 5190 [comprised related indi-
viduals], Set 2 N = 4583 [comprised unrelated (to each other and to
Set 1) individuals]). Quality control and normalisation was carried out
separately in the two sets using standard methods. Arrays were
scanned using a HiScan scanner (Illumina Inc., San Diego, California),
with initial inspection of array quality carried out in GenomeStudio
v2011.1. Additional quality control measures were implemented as
described in detail previously.28 Briefly, outlier sites and participants,
together with participants for whom there was a mismatch between
their predicted sex (based on DNAm data) and their recorded sex,
were excluded from both sets; samples were then normalised (sepa-
rately) using the Dasen method from the watermelon29 R package. The
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final DNAm dataset comprised data for 5087 individuals in Set 1 and
4450 individuals in Set 2. Participant data in the two sets were
analysed separately and then meta-analysed. After applying exclusion
criteria (see above), the current study included 4260 participants from
Set 1 and 3791 participants from Set 2 (full demographics in Table S2).
2.2.3 | Epigenetic estimates of age
Epigenetic age and age acceleration measures were calculated using
the online age calculator (https://dnamage.genetics.ucla.edu/)
developed by Horvath.10 Normalised DNAm beta-values were sub-
mitted to the calculator using the ‘Advanced Analysis for Blood Data’
option. Four DNAm-based estimates of age were calculated, namely,
Hannum30 and Horvath10 epigenetic age, DNAm GrimAge31 and
DNAm PhenoAge32 (see below), which all strongly correlated with
chronological age (Table S3) and with one another (Table S15). From
these estimates, four age-adjusted epigenetic age acceleration (EAA)
measures (intrinsic and extrinsic EAA [IEAA and EEAA, respectively],33
AgeAccelGrim31 and AgeAccelPheno32) were calculated (see below).
The age acceleration measures were uncorrelated with chronological
age (Table S3). In addition, the resulting EAA measures were only
weakly to moderately correlated with one another (Table S15),
suggesting they capture different aspects of DNAm ageing.
The Horvath epigenetic age was calculated based on methylation
levels at 353 CpG sites following the approach developed by
Horvath.10 Hannum epigenetic age was calculated based on DNAm
levels at the 71 CpGs identified by Hannum.30 From these DNAm age
estimates, we derived two measures for epigenetic age acceleration
that are either independent of blood cell counts or enhanced by
changes in blood cell composition, as described previously.33 In brief,
intrinsic epigenetic age acceleration (IEAA) is defined as the residual
term of a multivariate model regression estimated Horvath methyla-
tion age on chronological age, adjusting for blood cell counts estimated
from the methylation data (naive CD8+ T cells, exhausted CD8+ T
cells, plasmablasts, CD4+ T cells, natural killer cells, monocytes and
granulocytes), and is therefore by definition independent of blood
immune cell counts. Extrinsic epigenetic age acceleration (EEAA), on
the other hand, tracks age-related changes in blood cell composition
as well as cell-intrinsic epigenetic changes. It is estimated by first cal-
culating Hannum's DNAm age and second increasing the contribution
of three cell types whose abundance is known to change with age
(naive cytotoxic T cells, exhausted cytotoxic T cells and plasmablasts)
by forming a weighted average of Hannum's DNAm age estimate with
these three cell type estimates using the Klemera–Doubal approach.34
EEAA is defined as the residual term of univariate model regressing
the weighted estimated Hannum's epigenetic age in chronological age.
The DNAm GrimAge was developed by Lu et al.31 by first creating
DNAm-based surrogates for 12 plasma proteins and smoking pack-
years and thereafter regressing time to death on chronological age,
sex and these DNAm-based surrogates. This model selected chrono-
logical age, sex and DNAm-based surrogates for smoking pack-years
and seven plasma proteins (adrenomedullin, beta-2-microglobulin,
cystatin C, growth differentiation factor 15, leptin, plasminogen acti-
vation inhibitor 1 and tissue inhibitor metalloproteinase). The linear
combination of these variables is then used to estimate the DNAm
GrimAge. Adjusting DNAm GrimAge for chronological age generated
the measure of epigenetic GrimAge acceleration, AgeAccelGrim.31
The DNAm PhenoAge was developed by Levine et al.32 by first
regressing ageing-related mortality on 42 clinical markers and chrono-
logical age to select variables for inclusion in the phenotypic age
(PhenoAge) score. Ten variables (chronological age, albumin, creati-
nine, glucose and C-reactive protein levels, lymphocyte percentage,
mean cell volume, red blood cell distribution width, alkaline phospha-
tase and white blood cell count) were then used to calculate mortality
score, which was subsequently converted into units of years to create
the measure of PhenoAge. Thereafter, DNAm from whole blood was
used to predict this PhenoAge. This approach generated the selection
of 513 CpGs, and linear combination of the weighted CpGs yields the
DNAm PhenoAge.32 Adjusting DNAm PhenoAge for chronological
age generated the measure of phenotypic epigenetic age acceleration,
AgeAccelPheno.
2.3 | Statistical methods
All statistical analyses were performed in R (Versions 3.3.2, 3.6.1 and
4.0.1).35 Scaling by z-transformation was applied for all numeric
variables in the regression models.
2.3.1 | Association between alcohol use and brain
age in UKB
The variables AUDIT-C, AUDIT-P, AUDIT total scores and alcohol
consumption in units/week were entered separately into linear
models to test for association with residualised brain age. Smoking
status (coded at baseline as a binary value denoting whether individ-
uals had ever smoked or never smoked), age and sex were added as
covariates in each model in order to control for the effects of these
variables. As a sensitivity analysis, we additionally adjusted for age of
completing full-time education in the regression model (Figure S3).
Benjamini–Hochberg correction for false discovery rate (FDR) was
applied to the regression models.
2.3.2 | Association between alcohol consumption
and epigenetic age acceleration in GS:SFHS
Set 1 data (related subset of GS:SFHS) statistical analyses were con-
ducted in ASReml-R Version 3.0 (www.vsni.co.uk/software/asreml) to
fit a linear mixed model to control for relatedness within the sample
by fitting an inverse relationship matrix derived from pedigree infor-
mation as a random effect. Set 2 data (unrelated subset of GS:SFHS)
was analysed using linear regression (lm) function in base R. In each
model, EAA was fit as the dependent variable, and alcohol
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consumption (as log10[1 + units/week] to adjust for non-normal dis-
tribution) as the independent variable; sex, BMI, smoking pack-years
(at baseline, individuals were asked to self-report their tobacco expo-
sure [cigarettes/day], age when they started smoking and years since
stopped smoking, and pack-years variable was calculated as packs
[20 cigarettes/pack] smoked per day multiplied by years as a smoker)
and inverse relationship matrix fitted as a random effect only for Set
1 in ASReml were added as covariates. A sensitivity analysis was con-
ducted by additionally adjusting the models for years of education
(this information is collected from GS:SFHS participants in 10 catego-
ries corresponding to 0, 1–4, 5–9, 10–11, 12–13, 14–15, 16–17, 18–
19, 20–21, 22–23, or 24+ years of education). As smoking is strongly
associated with DNAm, further sensitivity analyses were conducted in
non-smoking individuals (i.e. who reported never having smoked
tobacco): n = 2207 in Set 1 and n = 1998 in Set 2. To combine the
coefficient estimates from the two sets into a single estimate, we
applied an inverse variance-weighted fixed-effects meta-analysis
model using the function metagen, implemented in the meta package
in R.36 FDR correction for multiple testing was applied across all fully
adjusted models (fully adjusted regressions in Sets 1 and 2 and meta-
analysis) and separately for the two sensitivity analyses. Results were
plotted using the function forest in the R package meta.
2.4 | Two-sample MR
Two-sample MR analysis was performed in R using the TwoSampleMR
package from MRBase37 using summary statistics extracted from non-
overlapping GWASs.
2.4.1 | Exposure GWAS: Alcohol consumption
(AUDIT-C) and AUD
Data on the genetic association with alcohol use were extracted from
Kranzler et al.22 This study was carried out in the Million Veteran Pro-
gramme population, which is based in the United States and therefore
highly unlikely to overlap with UKB or GS:SFHS populations made up
of British and Scottish individuals, respectively. Kranzler et al.22
reported a genome-wide significant association between 10 single
nucleotide polymorphisms (SNPs) and AUD, as well as 13 SNPs asso-
ciated with alcohol consumption as measured by AUDIT-C. These
SNPs were identified as independent by linkage disequilibrium
(LD) clumping using a 500-kb genomic window and r2 < 0.1.22 Here,
we extracted the summary statistics as reported in the European
ancestry population (see Tables S1 and S2 in Kranzler et al.22).
2.4.2 | Outcome GWASs
Brain age
GWAS for brain age acceleration was performed in a subset of
unrelated White British individuals in the UKB imaging cohort. 16,133
individuals were included using a relatedness cut-off of 0.05. To per-
form the GWAS, brain age was entered as the outcome variable and
age, sex, genotyping array and the 20 first principal components
derived from genotype data as covariates. From the results of this
analysis, we extracted the summary statistics (beta and standard error
of the effect allele of each SNP) for the 10 and 13 SNPs identified as
genome-wide significant by Kranzler et al.22 for AUD and AUDIT-C,
respectively. The full GWAS summary statistics are available here:
https://datashare.is.ed.ac.uk/handle/10283/3797. We used the Func-
tional Mapping and Annotation of Genome-Wide Association Studies
(FUMA)38 SNP2GENE function to extract results from the brain age
GWAS. In order to identify independently associated variants, clump-
based pruning was applied in FUMA using an r2 of 0.1 and a 1-Mb
sliding window using the UKB White British sample as the LD refer-
ence panel. See Table S17 for the 20 top hits and Figure S6 for a
Manhattan plot of main results. Using the GWAS summary statistics,
we calculated the SNP-based heritability (Table S18) and genetic over-
lap between brain age and 770 other disease traits (Table S19) using
LD score regression implemented in the online software LD Hub
(http://ldsc.broadinstitute.org/).39
Epigenetic age
Data on the genetic association with AgeAccelGrim and
AgeAccelPheno were extracted from McCartney et al.21 These
GWASs were conducted in 34,962 European ancestry individuals, and
a fixed-effects meta-analysis was performed to combine the summary
statistics.21 Supplementary tables were inspected to ensure that the
Million Veteran Programme cohort was not included in these meta-
GWASs. From the GWAS results (available here: https://datashare.is.
ed.ac.uk/handle/10283/3645), we extracted the corresponding sum-
mary statistics for the 13 SNPs identified as GW significant for
AUDIT-C by Kranzler et al.22
For SNPs unavailable in the outcome GWAS summary statistics,
proxy SNPs were searched for (https://ldlink.nci.nih.gov/?tab=
ldproxy) with a minimum LD R2 = 0.9. In AgeAccelGrim and
AgeAccelPheno GWASs, rs185177474 was not available; thus,
rs151242810 was used as a proxy (R2 = 0.976).
See Tables S4 and S5 for the full MR input testing causal effects
of AUDIT-C and AUD, respectively, on biological ageing.
We performed two MR analyses with brain age as the outcome,
where AUD or AUDIT-C were the exposures, respectively. One MR
analysis was performed with either AgeAccelGrim or AgeAccelPheno
as the outcome and AUDIT-C as the exposure. The main MR models
included 13 SNPs to probe for the causal effect of AUDIT-C on bio-
logical ageing and 10 SNPs to probe for the causal effect of AUD on
brain ageing.
We applied complementary two-sample MR methods (inverse
variance weighted [IVW], MR-Egger, weighted median and weighted
mode-based estimation). IVW was the main analysis with each of the
others providing sensitivity analyses, which each make different
assumptions about the nature of pleiotropy (where the genetic variant
associates with the outcome via an independent pathway to the expo-
sure). Therefore, the strongest evidence for a causal effect would be
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where the estimates from all methods are consistent. To test the suit-
ability of the MR-Egger method, the I2 statistic was calculated to
quantify the degree of regression dilution bias due to measurement
error of SNP-exposure effects.40 The mean F-statistic as an indicator
of instrument strength was also calculated (Table S7). We additionally
calculated the variance explained by the genetic instruments of
AUDIT-C and AUD using a modified method as described in41
(Table S20). Further, we used the MR-Egger intercept to test for the
presence of horizontal pleiotropy (Table S9) and Steiger filtering42 to
test for the most likely direction of effect (Tables S10–S13) and
calculated Cochran's Q to assess heterogeneity suggestive of pleiot-
ropy (Table S8). When there was evidence for a causal effect based
on the IVW model, we performed MR-Presso43 and Radial MR44 to
detect potential outliers.
3 | RESULTS
3.1 | Alcohol use associations with brain age
in UKB
Using linear regression, we found a consistent positive relationship
between brain age and the four measures of alcohol use (alcohol
units/week (N = 20,258, 52.1% female), AUDIT-C, AUDIT-P and
AUDIT-T (N = 14,710, 53.5% female)) (Figure 1), with higher levels of
self-reported alcohol consumption associated with a more advanced
brain age. The largest effect was found for alcohol consumption
measured in units/week (β = 0.078, 95% CI [0.066; 0.093],
p < 2.20  1016). Adjusting for education did not significantly alter
the outcome of this analysis for any measure of alcohol use
(Figure S3).
3.2 | Alcohol use associations with epigenetic age
in GS:SFHS
Linear regression and fixed-effects meta-analyses were used to
investigate associations between alcohol consumption (units/week)
and four measures of EAA (IEAA, EEAA, AgeAccelGrim and
AgeAccelPheno) in 8051 individuals in total (Set 1 n = 4260 [60.9%
female], Set 2 n = 3791 [55.3% female]) from the GS:SFHS cohort (full
demographics in Table S2). We found a positive association between
alcohol consumption and AgeAccelGrim (β = 0.053 [0.034; 0.071],
p = 1.48  107) and AgeAccelPheno (β = 0.077 [0.055; 0.100],
p = 2.18  1010), but not between alcohol consumption and IEAA or
EEAA (Figure 2). These results are robust to adjustment for years of
education (Figure S4).
As smoking is strongly associated with DNAm, we conducted a
second sensitivity analysis by exploring the associations between
alcohol consumption and AgeAccelGrim and AgeAccelPheno in a sub-
set of non-smoking participants (Figure 3). The positive associations
between alcohol consumption and the two EAA measures remained
significant in non-smokers, but the effect size was slightly (15%)
attenuated for AgeAccelGrim (β = 0.045 [0.026; 0.061],
p = 6.48  106) although it remained similar for AgeAccelPheno
(β = 0.074 [0.043; 0.104], p = 7.74  106).
3.3 | Testing for the causal influence of alcohol use
on accelerated brain age
Having demonstrated a consistent phenotypic association between
alcohol use and accelerated brain age, we used two-sample MR to
test a causal relationship between AUD/alcohol consumption
(AUDIT-C) and brain age (Figure 4). For AUD, the IVW model was
significant (β = 0.118 [0.003; 0.233], p = 0.044; mF = 73.744
[Table S7]) (Figure 4B) but not for AUDIT-C (Figure 4A), suggesting
that AUD, but not alcohol consumption levels, has a possible causal
effect on accelerated/advanced brain age. However, Steiger filtering
suggested that two of the genetic variants explained more variance
in the outcome, suggesting some potential for reverse causation
(Table S13). Additionally, Radial MR revealed rs570436 (Q = 4.854,
p = 0.028) as an outlier in the MR analysis of AUD and brain age,
and therefore, the analysis was repeated with this SNP excluded.
After removing the outlying SNP, the IVW model was no longer sig-
nificant (β = 0.092 [0.001; 0.185], p = 0.054), suggesting that the
F IGURE 1 Alcohol use is associated with advanced brain age. Linear regression models predicting residual brain age from AUDIT-C,
AUDIT-P, AUDIT-T and alcohol units, in current drinkers adjusted for smoking status. Plot shows standardised β coefficients with 95% confidence
intervals. CI, confidence interval
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outlier was driving the significant result for AUD (Figure S5),
although the biological function of this variant is not known, so
we cannot be sure whether it acts through alcohol consumption.
Together, these results provide limited evidence for a causal
effect of genetically instrumented AUD on brain age and no evi-
dence of a causal effect of alcohol use on brain age as measured by
AUDIT-C.
3.4 | Testing for the causal influence of alcohol
consumption on epigenetic age acceleration
As we observed, a significant association between alcohol consump-
tion and advanced GrimAge and PhenoAge in the observational analy-
sis, we used two-sample MR methods to test whether these effects
might be causal. Although the mean F-statistics suggest that the SNPs
included in the analyses are strong genetic instruments (mF = 79.058;
Table S7), there was no evidence to suggest a causal effect of alcohol
consumption (AUDIT-C) on the two EAA measures (Figure 5). Thus,
these results show that in this study, we find no evidence that the
association between alcohol consumption and accelerated epigenetic
age is causal.
4 | DISCUSSION
This study represents one of the largest systematic investigations of
alcohol use and biological ageing to date and is the first study investi-
gating possible causal relationships between alcohol use and acceler-
ated brain and epigenetic ageing using two-sample MR. We report
consistent positive associations between four measures of alcohol use
and accelerated brain age as well as alcohol consumption and two
measures of DNAm age acceleration (AgeAccelPheno and
AgeAccelGrim). MR analyses revealed limited evidence for the causal
F IGURE 2 Alcohol consumption is associated with two measures of advanced epigenetic age. Effects of alcohol consumption (units/week) on
(A) EEAA, (B) IEAA, (C) AgeAccelGrim and (D) AgeAccelPheno in fully adjusted models. Values on forest plot indicate standardised β with 95%
confidence intervals. Models are adjusted for sex, BMI and pack-years in Sets 1 and 2 and relatedness in Set 1 by fitting pedigree information as a
random effect in general linear mixed models using advanced restricted maximum likelihood (ASReml) method. Fixed-effects inverse variance-
weighted meta-analysis was applied using R package meta to combine the standardised coefficient estimates in Sets 1 and 2. FDR correction was
applied across all models in Sets 1 and 2 and all meta-analysis models (12 models in total). Sample size: n = 4260 in Set 1, n = 3791 in Set 2
(n = 8051 included in meta-analyses). CI, confidence interval; EEAA, extrinsic epigenetic age acceleration; FDR, false discovery rate; IEAA,
intrinsic epigenetic age acceleration; SE, standard error
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effect of AUD on accelerated brain age, although there was no evi-
dence to suggest a causal link between levels of alcohol consumption
and brain or epigenetic ageing.
In the present study, we demonstrate a positive association
between four measures of alcohol use and a metric of accelerated
brain ageing, derived from structural MRI. We show associations with
problematic alcohol use (AUDIT-P), alcohol consumption (AUDIT-C)
and total AUDIT scores, with the strongest phenotypic association
found for alcohol consumption in units/week. These results are
consistent with previous investigations showing that brain changes
associated with ageing are more pronounced in individuals with
higher levels of alcohol use2 and with previous reports of advanced
F IGURE 3 Alcohol consumption is associated with advanced GrimAge and PhenoAge in non-smokers. Effects of alcohol consumption
(units/week) on (A) AgeAccelGrim and (B) AgeAccelPheno in non-smoking participants. Values on forest plot indicate standardised β with 95%
confidence intervals. Models are adjusted for sex and BMI in Sets 1 and 2 and relatedness in Set 1 by fitting pedigree information as a random
effect in general linear mixed models using advanced restricted maximum likelihood (ASReml) method. Fixed-effects inverse variance-weighted
meta-analysis was applied using R package meta to combine the standardised coefficient estimates in Sets 1 and 2. FDR correction was applied
across all smoking sensitivity models in Sets 1 and 2 and all meta-analysis models (six models in total). Sample size: n = 2207 in Set 1, n = 1998 in
Set 2 (n = 4205 included in meta-analyses). CI, confidence interval; EEAA, extrinsic epigenetic age acceleration; FDR, false discovery rate; IEAA,
intrinsic epigenetic age acceleration; SE, standard error
F IGURE 4 Two-sample Mendelian randomisation analysis provides weak evidence for a causal effect of AUD on brain age acceleration.
(A) Two sample Mendelian randomisation of AUDIT-C on brain age. (B) Two-sample Mendelian randomisation of AUD on brain age. Data on the
genetic association with AUDIT-C and AUD were extracted from Kranzler et al.22 Summary statistics for these SNPs were extracted from a novel
GWAS of brain age (see Section 2). AUD, alcohol use disorder; CI, confidence interval; N SNP, number of SNPs included in the MR analysis
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brain age relative to peers in individuals who consume alcohol more
frequently.15,16 The present study provides evidence that brain
changes in response to excessive alcohol use resemble an early age-
ing process.
We further demonstrate a positive association between alcohol
consumption and accelerated DNAm PhenoAge and GrimAge, thus
expanding on the results of Fiorito et al.18 who showed positive asso-
ciation between alcohol consumption levels and accelerated
PhenoAge. However, we do not replicate previous findings showing
associations between self-reported alcohol consumption levels and
accelerated DNAm age derived from Hannum and Horvath
clocks,12,18 which could be attributed to differences in study
populations,12 differences in the use of alcohol use variables in the
models18 and the use of different DNAm arrays.12,18 Furthermore, the
first-generation clocks (Horvath and Hannum) were designed for the
Illumina 27 k and 450 k arrays, whereas PhenoAge and GrimAge were
developed using overlapping CpG sites on the Illumina 450 K and
EPIC arrays, and there are reports suggesting inaccurate Hannum and
Horvath age estimations when using the EPIC array.45 Importantly,
the novel PhenoAge and GrimAge estimators are shown to be
stronger predictors of mortality and lifestyle factors, including alcohol
use,18,31,32 which could be explained by the inclusion of CpG sites
associated with biomarkers of physiological dysregulation, disease and
mortality, whereas Hannum and Horvath clocks were designed to pre-
dict chronological age.
A major strength of the current study is the use of data from both
UKB and GS:SFHS, which enabled association studies to be conducted
in much larger samples from single cohorts compared with previous
reports (n = 20,258 for brain ageing in the current study compared
with n = 14,701,16 n = 12,11515 and n = 5272 in previous studies;
n = 8051 for the DNAm ageing in the current study compared with
n = 836,19 n = 368712 and n = 16,24518 [from 18 different cohorts
with each between 174 and 2817 participants] in previous studies).
An additional strength is the range of measurements enabling a sys-
tematic assessment of the association of four different self-reported
alcohol use measures with brain age acceleration as well as the
association between alcohol consumption and four different measures
of EAA.
Using two-sample MR, we report limited evidence suggesting a
causal link between the diagnosis of AUD and accelerated brain age-
ing, but no evidence for higher alcohol consumption causing acceler-
ated brain or epigenetic ageing. We replicate and expand on recent
findings showing significant genetic correlations between alcohol-
related phenotypes and epigenetic ageing, but no causal relationship
between alcohol use frequency and EAA measures as assessed by
MR.21 This suggests that the phenotypic association may arise from
confounding factors (e.g. other harmful lifestyle factors) that have
directional effects on both alcohol use and biological ageing. High
levels of psychiatric comorbidity with AUD46 represent another
possible confounder. For example, schizophrenia,47 major depressive
disorder48,49 and post-traumatic stress disorder50 are associated with
accelerated brain and/or epigenetic ageing. Furthermore, sensitivity
analyses revealed that some of the genetic variants used here for
alcohol use explain more variance in the outcome (brain or DNAm
ageing), suggesting potential reverse causation. Finally, the Million
Veteran Programme sample used for the GWAS of AUD and alcohol
consumption comprises predominantly male armed forces veterans.22
Thus, it may not be representative of the whole population, as there is
evidence that alcohol use and AUD have higher prevalence in males1
and genetic mechanisms might differ between sexes. Additionally,
F IGURE 5 Two-sample Mendelian randomisation analysis shows no evidence for causal effect of alcohol consumption on measures of
epigenetic age acceleration: (A) AgeAccelGrim and (B) AgeAccelPheno. Data on the genetic association with alcohol use (AUDIT-C) were
extracted from Kranzler et al.22 Summary statistics for these SNPs were extracted from GWASs for AgeAccelGrim and AgeAccelPheno conducted
by McCartney et al.21 rs185177474 was not available in AgeAccelGrim and AgeAccelPheno summary statistics; thus, rs151242810 was used as a
proxy (R2 = 0.976; see Section 2). CI, confidence interval; N SNP, number of SNPs included in the MR analysis
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there are differences in the phenotypes used in the current study and
the ones used in the GWAS for AUD and alcohol consumption by
Kranzler et al.22 (e.g. clinically diagnosed AUD vs AUDIT-P). Future
longitudinal studies combined with more experimental approaches
could help elucidate the mechanisms linking alcohol use with biologi-
cal ageing and their interactions.
Several other limitations need to be addressed when interpreting
these findings. First, this study relied on self-reported measures of
alcohol use that might be inaccurate due to response biases. Whereas
there are traditionally few alternatives, the validation of approaches
such as estimation of alcohol drinking via the generation of a compos-
ite score for alcohol use from DNAm data19,51 or other biological data
(e.g. liver enzyme levels as investigated in association with EAA previ-
ously17) could help to overcome the need to rely on self-reported
measures. Second, although we investigated the associations between
problematic alcohol use (AUDIT-P) and brain ageing, we were unable
to conduct a similar evaluation in association with DNAm ageing
measures. Additionally, different drinking patterns may be important.
It was recently suggested that the relationship between educational
attainment and adverse health outcomes is mediated by specific pat-
terns of alcohol use, such as binge drinking, rather than total alcohol
consumption.52 Thus, the focus on overall alcohol consumption in the
present study might preclude the detection of a causal relationship.
Finally, we investigated the associations between alcohol use and
brain ageing or blood DNAm ageing in two separate large cohorts. It
would be of interest in future studies to investigate the associations
between alcohol use and the two types of biological ageing measures
in the same individuals and evaluate the relationship between brain
and DNAm ageing.
To conclude, in one of the largest studies on the relationship
between alcohol use and biological ageing to date, and a first investi-
gation of the causal relationship between the two using MR, we
report a consistent association between higher levels of alcohol con-
sumption and accelerated biological ageing. The present study found
very limited evidence that the diagnosis of AUD might be causally
linked to accelerated brain ageing; however, these results need to be
interpreted with caution as they are driven by an outlier variant with
unknown biological function and there is some limited evidence of
potential reverse causation. Using two-sample MR, we additionally
found no evidence for a causal link between alcohol consumption
levels and biological ageing indicated by brain or DNAm ageing
measures. The positive phenotypic associations between alcohol
consumption and brain and epigenetic ageing add to the body of liter-
ature suggesting that alcohol use is associated with biomarkers
predicting early ageing and mortality; however, the precise nature of
this relationship remains to be identified in future studies.
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